UNSPSC 51281621: Propikacin

This classification denotes an aminoglycoside antibiotic with the molecular formula C21H43N5O12, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9X6F5H479X, chemically known as uk 31,214 but generally known as propikacin, which bears US NIH Compound Identifier 68557. European Medicines Agency schedules Propikacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10107MIG. The term PROPIKACIN is an International Non-Proprietary Name.

UNSPSC 51281621 Propikacin is a Commodity code representing pharmaceutical products and medical supplies being procured by state and local health agencies, first-responder departments, and cooperative purchasing alliances. Recent solicitations under this code show state and local governments buying naloxone, over-the-counter pharmaceuticals, generic multi-source drugs, and emergency medical supplies—products with direct public health and emergency-response applications. The issuing bodies span county health departments (Seminole County, Florida), municipal fire and rescue services (City of Tampa), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing vehicles (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). No standout repeat buyer appears across the recent opportunities, though cooperative purchasing alliances are emerging as a significant procurement mechanism for pharmaceutical aggregation across multiple jurisdictions.

The code shows recent activity concentrated in Florida and Minnesota, with engagement from Texas and Oregon through cooperative arrangements. Representative opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) for 1,900 annual units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to the Seminole County Community Health Building; the City of Tampa's IFB 26P00145 (posted March 25, 2026, due March 13, 2026) for 169 line items of medical and first aid supplies estimated at $700,000 and designated as a sheltered market opportunity for certified Small Local Business Enterprises with a 5 percent bid discount; and MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) seeking multiple generic pharmaceutical and OTC product contracts across participating state and local facilities with awards effective July 1, 2026. Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) signals emerging state interest in direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and wholesaler channels.